- Project Summary
- Study Duration
- Objectives
- Implementation Site
- Team Members
Project Summary
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
Study Duration
9 months
Objectives
The co-primary endpoints were:
 (1) non-inferiority of immunogenicity of the Vi-DT vaccine (pooled groups A–C) versus the Vi-TT vaccine (group D) at 4 weeks after vaccination, measured by the anti-Vi IgG seroconversion rate, which was defined as the proportion of participants with a four-fold or greater increase in antibody titres compared with baseline; and
 (2) the lot-to-lot consistency of the Vi-DT vaccine, measured by immune equivalence of the anti-Vi IgG geometric mean titre (GMT) at 4 weeks after receipt of the three Vi-DT vaccine lots (lot 1 vs lot 2, lot 1 vs lot 3, and lot 2 vs lot 3).
Implementation Site
Dhulikhel Hospital, Baluwa Health Center
Team Members
Principal Investigator(s):Â Prof. Dr. Rajeev Shrestha, Dr. Dipesh Tamrakar
Co-Investigator(s): Dr. Amit Khadgi, Dr. Pranodan Poudel, Dr. Srijana Dongol Singh, Mr. Surendra Madhup, Dr. Anmol Purna Shrestha, Dr. Rajendra Tamrakar
Project Coordinator:Â Ms. Pragya Thapa, Dr. Amit Khadgi
Research Assistants:Â Ms. Anita Shrestha, Ms. Reena Kharbuja, Ms. Usha Acharya, Ms. Shanti Bogati, Ms. Sunita Shrestha, Ms. Sapana Khadka, Ms. Jyoti Palanchoke, Ms. Shreena Shrestha, Ms. Sunaina Shrestha



For more detailed Information, Please contact:Â rajeev.shrestha@kusms.edu.np / rmaleku@hotmail.com or dipesht@kusms.edu.np